Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations
09:02am, Wednesday, 30'th Oct 2024
GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy skidded.
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
08:58am, Wednesday, 30'th Oct 2024
Wednesday, GSK Plc GSK reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of $10.78 bi
GSK Stock Drops as UK Firm Posts Underwhelming Results
08:40am, Wednesday, 30'th Oct 2024
GSK's (GSK) shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales.
GSK cuts vaccine sales target on reduced demand
07:17am, Wednesday, 30'th Oct 2024
U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.
GSK falls 3% as vaccines disappoint (again)
04:17am, Wednesday, 30'th Oct 2024
Dedicated followers of GSK PLC (LSE:GSK, NYSE:GSK) will have been aware of analysts' growing unease around the performance of its vaccine franchise - backed up by prescription data. Third-quarter resu
GSK lowers 2024 vaccine sales forecast
03:06am, Wednesday, 30'th Oct 2024
GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
06:30pm, Monday, 28'th Oct 2024
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for
IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing IDEAYA's 5th potential first-in-class clinical program
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
09:30am, Saturday, 26'th Oct 2024
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company's diversified portfolio in
GSK looking to moveon from Zantac in forthcoming update
06:03am, Friday, 25'th Oct 2024
GSK PLC (LSE:GSK, NYSE:GSK) share price bump on settlement of most of its Zantac litigation claims has reversed recently on concerns about two key products, Arexvy and Shingrix, in the important US ma
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--New data for AREXVY, GSK's RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
11:06am, Wednesday, 23'rd Oct 2024
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK has earnings estimate cut, slow shingles vaccine uptake cited
09:16am, Monday, 21'st Oct 2024
UBS has cut its earnings per share (EPS) estimate for GSK PLC (LSE:GSK, NYSE:GSK) by 5% for fiscal years 2024 and 2025. The decision comes ahead of GSK's third-quarter results, expected on 30 October,
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
01:11pm, Thursday, 17'th Oct 2024
The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.
3 Vaccine Stocks to Watch as Flu Season Approaches
02:54pm, Wednesday, 16'th Oct 2024
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring.
